MedTrace Logo

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

NCT03445013 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-03-27

No results posted yet for this study

Summary

The objectives of this study are to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of SB414 in subjects with mild to moderate plaque psoriasis.

Conditions

Interventions

DRUG

SB414 6%

Twice daily

DRUG

Vehicle

Vehicle Comparator

Sponsors & Collaborators

  • Novella Clinical

    collaborator OTHER

  • Novan, Inc.

    lead INDUSTRY

Principal Investigators

  • Tomoko Maeda-Chubachi, MD · Novan, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-13
Primary Completion
2018-01-31
Completion
2018-02-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03445013 on ClinicalTrials.gov